- The FDA has signed off Jounce Therapeutics Inc's JNCE Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of $25 million from Gilead Sciences Inc GILD.
- JTX-1811, referred to as GS-1811 in Gilead's pipeline, is a monoclonal antibody to deplete immunosuppressive tumor-infiltrating T regulatory cells selectively.
- Under the terms of the September 2020 agreement, Gilead invested $35 million in Jounce's common stock and made an $85.0 million upfront payment to Jounce.
- Price Action: JNCE shares are up 5.7% at $7.39 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
